Home >> Healthcare >> Food & Beverage >>

Vasculitis - Pipeline Review, H2 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 99 | Code: MRS - 35130

Vasculitis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Vasculitis - Pipeline Review, H2 2015’, provides an overview of the Vasculitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vasculitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vasculitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vasculitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vasculitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vasculitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Vasculitis Overview 8
Therapeutics Development 9
Pipeline Products for Vasculitis - Overview 9
Pipeline Products for Vasculitis - Comparative Analysis 10
Vasculitis - Therapeutics under Development by Companies 11
Vasculitis - Therapeutics under Investigation by Universities/Institutes 12
Vasculitis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Vasculitis - Products under Development by Companies 16
Vasculitis - Products under Investigation by Universities/Institutes 18
Vasculitis - Companies Involved in Therapeutics Development 19
AnGes MG, Inc. 19
Aprogen, Inc. 20
ChemoCentryx, Inc. 21
Epirus Biopharmaceuticals, Inc. 22
F. Hoffmann-La Roche Ltd. 23
GlaxoSmithKline Plc 24
Hemostemix Ltd 25
K-Stemcell Co., Ltd. 26
Panacea Biotec Limited 27
Pfizer Inc. 28
Sandoz International GmbH 29
Stempeutics Research Private Limited 30
Teijin Pharma Limited 31
XOMA Corporation 32
Vasculitis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
ACP-01 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
belimumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
beperminogene perplasmid - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CCX-168 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
gevokizumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
immune globulin (human) - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
PF-1355 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
rituximab biosimilar - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
rituximab biosimilar - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
rituximab biosimilar - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
rituximab biosimilar - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Stempeucel - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
tocilizumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Vascostem - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Vasculitis - Recent Pipeline Updates 72
Vasculitis - Dormant Projects 92
Vasculitis - Product Development Milestones 93
Featured News & Press Releases 93
Jun 01, 2015: Stempeutics Receives Orphan Drug Designation (ODD) in the European Union for its Novel Stem Cell Drug "Stempeucel" for the Treatment of Thromboangiitis Obliterans 93
Mar 23, 2015: Stempeutics Receives Advanced Therapy Medicinal Product (ATMP) Classification From European Medicines Agency (EMA) for its Novel Stem Cell Drug 'Stempeucel' 93
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 94
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 95
Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis 95
Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 95
May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress 96
Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis 97
Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology 97
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 98
Disclaimer 99

List of Tables
Number of Products under Development for Vasculitis, H2 2015 9
Number of Products under Development for Vasculitis - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Development by Companies, H2 2015 (Contd..1) 17
Products under Investigation by Universities/Institutes, H2 2015 18
Vasculitis - Pipeline by AnGes MG, Inc., H2 2015 19
Vasculitis - Pipeline by Aprogen, Inc., H2 2015 20
Vasculitis - Pipeline by ChemoCentryx, Inc., H2 2015 21
Vasculitis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 22
Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 23
Vasculitis - Pipeline by GlaxoSmithKline Plc, H2 2015 24
Vasculitis - Pipeline by Hemostemix Ltd, H2 2015 25
Vasculitis - Pipeline by K-Stemcell Co., Ltd., H2 2015 26
Vasculitis - Pipeline by Panacea Biotec Limited, H2 2015 27
Vasculitis - Pipeline by Pfizer Inc., H2 2015 28
Vasculitis - Pipeline by Sandoz International GmbH, H2 2015 29
Vasculitis - Pipeline by Stempeutics Research Private Limited, H2 2015 30
Vasculitis - Pipeline by Teijin Pharma Limited, H2 2015 31
Vasculitis - Pipeline by XOMA Corporation, H2 2015 32
Assessment by Monotherapy Products, H2 2015 33
Number of Products by Stage and Target, H2 2015 35
Number of Products by Stage and Mechanism of Action, H2 2015 37
Number of Products by Stage and Route of Administration, H2 2015 39
Number of Products by Stage and Molecule Type, H2 2015 41
Vasculitis Therapeutics - Recent Pipeline Updates, H2 2015 72
Vasculitis - Dormant Projects, H2 2015 92

List of Figures
Number of Products under Development for Vasculitis, H2 2015 9
Number of Products under Development for Vasculitis - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 15
Assessment by Monotherapy Products, H2 2015 33
Number of Products by Top 10 Targets, H2 2015 34
Number of Products by Stage and Top 10 Targets, H2 2015 34
Number of Products by Top 10 Mechanism of Actions, H2 2015 36
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 36
Number of Products by Top 10 Routes of Administration, H2 2015 38
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 38
Number of Products by Top 10 Molecule Types, H2 2015 40
Number of Products by Stage and Top 10 Molecule Types, H2 2015 40

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)2000 View Pricing